To help you understand what is going on in the drug and pharmaceutical industry and what we expect to happen in the future, our highly experienced Kiplinger Letter team will keep you abreast of the latest developments and forecasts (Get a free issue of The Kiplinger Letter or subscribe). You'll get all the latest news first by subscribing, but we will publish many (but not all) of the forecasts a few days afterward online. Here’s the latest…
At the very least, 2024 will be better than 2023 for the pharma industry. Swiss pharma giant Roche will score the most sales ($55 billion) of any drugmaker next year on the strength of its biologics portfolio, including Ocrevus, a treatment for MS, as well as anti-cancer agent Tecentriq and hemophilia drug Hemlibra.
Johnson & Johnson (JNJ), Merck, AbbVie (ABBV) and Pfizer will exceed $50 billion in sales, too. But Pfizer, the world’s top-selling drugmaker last year, will fall to fifth place due to declining sales for its pandemic-related treatments.
Another notable change: Novo Nordisk will enter the top 10, supplanting GSK (formerly GlaxoSmithKline). Novo Nordisk will boast the two biggest generators of new drug sales, which are both weight loss-related: Wegovy ($4 billion in new sales) and Ozempic ($3 billion).
From just $107.88 $24.99 for Kiplinger Personal Finance
Be a smarter, better informed investor.
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Combined, total sales of the drugs, which both employ the same active ingredient, Semaglutide, will rival those of Keytruda, the world’s best-selling pharmaceutical. Keytruda, a cancer immunotherapy drug manufactured and marketed by Merck, will generate over $25 billion this year.
Beyond Keytruda, Wegovy and Ozempic, other top sellers include Sanofi and Regeneron’s Dupixent, which is used to treat allergic diseases like eczema, asthma and nasal polyps, Eliquis, the Pfizer and Bristol Myers Squibb drug used to prevent blood clots, and Gilead’s Biktarvy, a fixed-dose combination medication for the treatment of HIV and AIDS.
This forecast first appeared in The Kiplinger Letter, which has been running since 1923 and is a collection of concise weekly forecasts on business and economic trends, as well as what to expect from Washington, to help you understand what’s coming up to make the most of your investments and your money. Subscribe to The Kiplinger Letter.
Related Content
-
Stocks Hit Fresh Highs Ahead of the Fed As Earnings Pump Optimism: Stock Market TodaySHW and UNH were two of the best Dow Jones stocks Tuesday, thanks to solid earnings reports, and MSFT closed with a $4 trillion market cap.
-
Selling Your Haunted House? What You Have to Tell Buyers (and What You Don’t)You don’t need ghosts to spook buyers, sometimes a home’s past is enough. Here’s what sellers should know about disclosure laws, pricing and perception when a property has a haunted history.
-
Will AI Videos Disrupt Social Media?The Kiplinger Letter With the introduction of OpenAI’s new AI social media app, Sora, the internet is about to be flooded with startling AI-generated videos.
-
What Services Are Open During the Government Shutdown?The Kiplinger Letter As the shutdown drags on, many basic federal services will increasingly be affected.
-
The Economy on a Knife's EdgeThe Letter GDP is growing, but employers have all but stopped hiring as they watch how the trade war plays out.
-
Banks Are Sounding the Alarm About StablecoinsThe Kiplinger Letter The banking industry says stablecoins could have a negative impact on lending.
-
Apple Readies for AI Upgrade with New iPhonesThe Kiplinger Letter The tech giant has stumbled when it comes to artificial intelligence, but a new batch of iPhones will help it make headway.
-
Japan Enters a New Era of Risk and ReformThe Kiplinger Letter Japan has entered a pivotal moment in its economic history, undertaking ambitious policy and structural reforms to escape from decades of stagnation.
-
How Consumers Are Tinkering with Cutting-Edge AIThe Kiplinger Letter Companies launching artificial intelligence tools are jostling for consumer attention. Some products are already building a deep connection with users.
-
After Years of Stagnant Growth, Hope Emerges for EU EconomyThe Kiplinger Letter Can a German fiscal push outweigh French political peril?
